LIPOSOME TECHNOLOGY ENTERS AGREEMENT WITH ERBAMONT

LIPOSOME TECHNOLOGY ENTERS AGREEMENT WITH ERBAMONT

Liposome Technology Inc., a biomedical company specializing in developing liposome-based delivery systems for therapeutic products, has entered into a development and licensing agreement with Erbamont NV.

Under the agreement, the companies will co-develop Erbamont oncology products, which will be incorporated in the proprietary delivery systems developed by LTI. Erbamont oncology products are being considered for inclusion in the liposome delivery systems.The first product to be considered in this co-development will be Adriamycin, which is a widely used anti-cancer drug in the United States and Western Europe.

Erbamont, located in Stamford, Conn., is a leader in the discovery, manufacture and sale of anti-cancer chemotherapeutic drugs.